HELICOBACTER PYLORI - IgG (ELFA)
Bacterial/ Viral0 parametersReport in 48HrsAt Home
No Fasting Required
Details
Detects the presence of IgA antibodies against H. pylori bacteria in the blood using the CLIA method
₹850₹2,500
66% OFF
FREE:AI Insights
HELICOBACTER PYLORI - IgG (ELFA) Test Information Guide
- Why is it done?
- Detects IgG antibodies against Helicobacter pylori bacteria to determine current or past infection status
- Primary indications for ordering:
- Evaluation of chronic or recurrent peptic ulcer disease
- Investigation of chronic gastritis or dyspepsia symptoms
- Screening in areas with high H. pylori prevalence
- Risk stratification for gastric cancer in high-risk populations
- Family history of H. pylori infection or gastric malignancy
- Typical timing and circumstances:
- Initial serology testing when H. pylori infection is suspected
- Can be performed at any time and does not require active infection to detect antibodies
- Particularly useful in asymptomatic individuals or when urea breath test is not available
- Normal Range
- Reference Values:
- Negative: < 0.9 Index or < 10 mIU/mL (laboratory-dependent)
- Borderline/Equivocal: 0.9 - 1.1 Index (may require repeat testing or confirmation)
- Positive: > 1.1 Index or > 10 mIU/mL (indicates presence of H. pylori antibodies)
- Units of Measurement:
- Index value (optical density ratio) or mIU/mL (milli-International Units per milliliter)
- ELFA (Enzyme-Linked Fluorescence Assay) methodology provides quantitative results
- Interpretation Guide:
- Negative Result (Normal): Indicates absence of H. pylori antibodies; unlikely to have current or recent H. pylori infection; however, does not completely exclude very recent infection (window period before antibody formation)
- Positive Result (Abnormal): Indicates presence of H. pylori IgG antibodies, suggesting current or past infection; may indicate active infection or past exposure; requires clinical correlation with symptoms and additional confirmatory testing if first positive result
- Borderline Result: Requires repeat testing or alternative confirmation methods due to technical or biological variables
- Reference Values:
- Interpretation
- Detailed Result Interpretation:
- Positive IgG Result:
- Indicates H. pylori infection at some point; IgG antibodies persist for years even after successful eradication
- Cannot differentiate between active infection and past exposure without additional testing (IgM or IgA serology, stool antigen, urea breath test, or biopsy)
- Higher index values (significantly elevated) may suggest more recent or active infection
- Negative IgG Result:
- Suggests no prior or current H. pylori infection
- Very recent infection may produce false negative result (window period, typically 1-2 weeks)
- May need repeat testing if high clinical suspicion exists
- Positive IgG Result:
- Factors Affecting Results:
- Recent proton pump inhibitor (PPI) use: May suppress antibody levels but does not eliminate seropositivity
- Recent antibiotic therapy: May affect bacterial load but does not eliminate antibodies
- Time since infection: IgG persists indefinitely after successful treatment
- Immunosuppression: May result in false negative results due to impaired antibody production
- Cross-reactivity: Other Helicobacter species may cause false positive results in rare cases
- Clinical Significance of Result Patterns:
- Symptomatic Patient + Positive IgG: Warrants further investigation; consider confirmatory testing to determine if infection is active
- Asymptomatic Patient + Positive IgG: May indicate past infection; eradication therapy generally recommended only if high-risk for complications
- Post-Treatment Monitoring + Still Positive IgG: Expected finding; IgG remains positive for years after successful eradication
- Symptomatic Patient + Negative IgG: Effectively rules out H. pylori infection in most cases; consider other differential diagnoses
- Detailed Result Interpretation:
- Associated Organs
- Primary Organ System:
- Gastrointestinal tract, specifically the stomach and duodenum
- Gastric mucosa colonization by H. pylori leads to chronic inflammation
- Medical Conditions Associated with H. pylori Infection:
- Peptic ulcer disease (duodenal and gastric ulcers): H. pylori causes approximately 90% of duodenal ulcers and 70% of gastric ulcers
- Chronic gastritis: Persistent inflammation of gastric mucosa, leading to atrophy and achlorhydria
- Gastric cancer (adenocarcinoma): H. pylori is a Class 1 carcinogen; increases risk of intestinal-type gastric cancer
- Gastric mucosa-associated lymphoid tissue (MALT) lymphoma: H. pylori-associated low-grade lymphoma
- Functional dyspepsia: Association remains under investigation
- Intestinal metaplasia: Precancerous condition of gastric mucosa
- Diseases This Test Helps Diagnose:
- Active H. pylori infection: Positive IgG with supporting clinical features and confirmatory tests
- Past or latent H. pylori infection: Positive IgG alone
- Rules out H. pylori etiology of peptic ulcer disease or dyspepsia when negative
- Potential Complications Associated with Abnormal Results:
- Hemorrhage from ulcer erosion into blood vessels
- Perforation of gastric or duodenal wall leading to peritonitis
- Gastric outlet obstruction from scarring
- Progression to gastric cancer over decades of untreated infection
- MALT lymphoma transformation
- Primary Organ System:
- Follow-up Tests
- Confirmatory Tests for Positive IgG Results:
- Urea Breath Test (UBT): Non-invasive, detects active infection; preferred confirmatory test
- H. pylori Stool Antigen Test: Detects active infection; can be used for diagnosis and post-treatment confirmation
- H. pylori Culture or PCR from Gastric Biopsy: Gold standard for diagnosis when endoscopy performed; allows antimicrobial susceptibility testing
- H. pylori IgA and IgM Serology: May provide information about infection recency when combined with IgG
- Recommended Additional Tests Based on Clinical Presentation:
- Upper Endoscopy (Esophagogastroduodenoscopy or EGD): For symptomatic patients; allows direct visualization and biopsy for histology and culture
- Rapid Urease Test (RUT) on Endoscopic Biopsies: Quick detection of urease-producing H. pylori
- Gastric Biopsy Histopathology: Gold standard for diagnosing H. pylori gastritis and detecting atrophy, metaplasia, or dysplasia
- Serum Pepsinogen I and II Levels: Assess gastric mucosal atrophy in chronic H. pylori infection
- Complete Blood Count (CBC): May show anemia from chronic GI bleeding
- Monitoring After Treatment:
- Post-treatment confirmation (4 weeks after completing therapy): Urea breath test, stool antigen test, or endoscopic biopsy preferred over serology
- H. pylori IgG will remain positive indefinitely after successful eradication; do not use for post-treatment assessment
- Annual surveillance endoscopy may be considered for patients with extensive gastric atrophy or intestinal metaplasia
- Related Tests Providing Complementary Information:
- Gastrin Level: Elevated in achlorhydria secondary to H. pylori-induced atrophy
- H. pylori Resistance Testing (if available): May guide eradication therapy selection in difficult-to-treat cases
- Confirmatory Tests for Positive IgG Results:
- Fasting Required?
- Fasting Status:
- NO fasting is required for H. pylori IgG serology (ELFA)
- Blood sample can be collected at any time of day
- Medications to Avoid or Consider:
- Proton Pump Inhibitors (omeprazole, lansoprazole, pantoprazole, etc.): Discontinue 2 weeks prior to testing if possible; they may suppress IgG levels without eliminating seropositivity
- H2-receptor antagonists (ranitidine, famotidine): May slightly affect results; discontinue 2 weeks prior if feasible
- Antibiotics: Discontinue at least 4 weeks prior to testing to allow for accurate serological results
- Note: Discuss with physician if discontinuing medications may harm the patient
- Other Patient Preparation Requirements:
- No special preparation needed; routine venipuncture technique for serum blood collection
- Serum sample (no anticoagulant): Blood collected in serum separator tube (SST) or plain tube
- Allow blood to clot and centrifuge according to laboratory protocol
- No specific patient positioning or preparation required
- Notify healthcare provider of any recent medications or supplements
- Fasting Status:
How our test process works!
